Moolec Science (MLEC)
NASDAQ:MLEC
Want to see MLEC full AI Analyst Report?
MLEC Stock Chart & Stats
$8.93
-$0.04(-4.25%)
At close: 4:00 PM EST
$8.93
-$0.04(-4.25%)
Day’s Range― - ―
52-Week Range$3.08 - $120.00
Previous CloseN/A
Volume11.69K
Average Volume (3M)209.37K
Market Cap
$5.27M
Enterprise Value$251.58M
Total Cash (Recent Filing)$1.93M
Total Debt (Recent Filing)$22.09M
Price to Earnings (P/E)―
Beta-0.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding726,118
10 Day Avg. Volume506,476
30 Day Avg. Volume209,369
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.12
P/FCF Ratio-1.35
Enterprise Value/Market Cap47.76
Enterprise Value/Revenue32.12
Enterprise Value/Gross Profit-393.40
Enterprise Value/Ebitda-48.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Molecular FarmingMoolec's core technology—engineering crops to produce target proteins and oils—is a durable competitive asset. Molecular farming embeds production into agricultural supply chains, enabling scalable ingredient manufacturing and potential cost advantages versus fermentation or animal sources, supporting long-term commercial adoption.
Commercial Traction And Improving MarginsA very large revenue ramp and a jump in gross margin to ~34% indicate the business is moving from R&D toward commercial sales. Sustained revenue diversification and margin expansion suggest product-market fit and improved unit economics, which are essential for durable cash generation if the trend persists.
Restored Nasdaq Compliance & Equity ImprovementRegaining listing compliance backed by preference conversions and credit disbursements materially reduces short-term delisting risk and stabilizes access to U.S. capital markets. A stronger equity base provides a firmer platform for partnerships, licensing and future financing to support commercialization initiatives.
Bears Say
Negative Equity & High LeverageNegative equity and elevated borrowings create a structurally weak capital structure, increasing refinancing and solvency risk. This reduces strategic flexibility, can hamper partner confidence, and may force dilutive capital raises or onerous debt terms, constraining long-term investment in commercialization.
Persistent Cash BurnOngoing negative operating and free cash flows imply the business remains reliant on external funding. Persistent cash burn can pressure execution timelines, limit the ability to scale production or secure processing partnerships, and increase the probability of dilutive financing during critical commercialization phases.
Losses Despite One-off GainsSubstantial accounting losses, even with improved revenue, indicate costs and overhead still outpace core operating income. Reliance on non-recurring gains to report profit masks underlying operating weakness, challenging sustainable earnings conversion and long-term investor confidence without structural cost reduction or stronger recurring sales.
Moolec Science News
MLEC FAQ
What was Moolec Science’s price range in the past 12 months?
Moolec Science lowest stock price was $3.08 and its highest was $120.00 in the past 12 months.
What is Moolec Science’s market cap?
Moolec Science’s market cap is $5.27M.
When is Moolec Science’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Moolec Science’s earnings last quarter?
Currently, no data Available
Is Moolec Science overvalued?
According to Wall Street analysts Moolec Science’s price is currently Overvalued.
Does Moolec Science pay dividends?
Moolec Science does not currently pay dividends.
What is Moolec Science’s EPS estimate?
Moolec Science’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moolec Science have?
Moolec Science has 726,118 shares outstanding.
What happened to Moolec Science’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Moolec Science?
Currently, no hedge funds are holding shares in MLEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moolec Science
Moolec Science S.A. is an innovative biotechnology firm specializing in the development of plant-grown animal proteins. Leveraging a transformative method called Molecular Farming, the company is poised to disrupt the alternative protein market. Their product lines and research and development efforts capitalize on the inherent agricultural benefits of select host crops, such as soybeans and peas. Globally, Moolec maintains operations across the United States, Europe, and South America. Established in 2008, the company is headquartered in Luxembourg.
Technical Analysis
AIM ImmunoTech
―
Ensysce Biosciences
―
Cyclerion Therapeutics
―
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
0.01% Mutual Funds
― Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---